Expression and Prognostic Value of Mirna-29B in Peripheral Blood for Endometrial Cancer

Abstract

Aim: We explored the role of miR-29b expression in endometrial cancer (EC) progression and patient prognosis. Materials & methods: Patients with primary or metastatic EC (n = 356), patients with endometrial benign tumors (n = 149) and healthy female subjects (n = 155) were collected. We assessed the diagnostic value of miR-29b expression for EC using a receiver operating characteristic curve. Results: The miR-29b expressions were lower in patients with primary or metastatic EC. Using miR-29b expression to diagnose EC produced 0.976 area under the curve, 96.1% sensitivity and 97.9% specificity. Cox proportional hazard regression model verified a low miR-29b expression and is an unfavorable prognostic indicator for EC. Conclusion: We conclude that downregulated miR-29b expression correlates with poor EC prognosis and is helpful to evaluate the EC prognosis.

Keywords::

• clinicopathological features
• endometrial cancer
• FIGO staging
• lymph node metastasis
• miRNA-29b
• prognosis

Acknowledgements

The authors acknowledge the helpful comments on this paper received from our reviewers.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

This study was approved by the Ethics Committee of our hospital. All participating patients have agreed to and signed informed consents.